Looking ahead in 2026, I think the best investment opportunities on the ASX could come from a mix of proven compounders, long-term growth stories, and businesses that have already shown they can execute through different market conditions.
Rather than chasing what's hot, I would focus on ASX shares with large addressable markets, strong competitive advantages, and management teams that have a track record of delivering.
With that in mind, here are 10 ASX shares that I would buy in 2026:
Image source: Getty Images
Life360 Inc. (ASX: 360)
Life360 is building a global consumer platform around family safety and location sharing. With 91 million monthly active users and growing subscription penetration, it has a long runway for monetisation as it scales internationally.
CSL Ltd (ASX: CSL)
CSL remains one of Australia's highest-quality global businesses. Despite recent share price weakness, its leadership in plasma therapies gives it exposure to powerful long-term healthcare demand. After a disappointing time in 2025, I think this biotech could rebound strongly in 2026.
DroneShield Ltd (ASX: DRO)
DroneShield operates in a niche that is only becoming more important. Counter-drone technology is now a priority for defence and security agencies worldwide, and DroneShield is emerging as a key specialist provider. With defence budgets increasing materially, it looks well-placed to benefit.
Goodman Group (ASX: GMG)
Goodman offers a blend of stability and growth. Its global logistics and data centre assets sit at the heart of e-commerce, cloud computing, and artificial intelligence infrastructure. I think it represents one of the best buy and hold options on the Australian share market.
Lovisa Holdings Ltd (ASX: LOV)
Lovisa has quietly become one of the ASX's best retail growth stories. Its fast-fashion jewellery model continues to scale globally, supported by disciplined store rollouts and strong unit economics. It may have over 1,000 stores globally, but its expansion is far from over.
ResMed Inc. (ASX: RMD)
ResMed addresses a massive and underpenetrated market in sleep apnoea and respiratory care. With ongoing innovation in connected devices and software, it remains well positioned for long-term growth. Especially given the estimated 1 billion sufferers of sleep apnoea globally.
Telix Pharmaceuticals Ltd (ASX: TLX)
Telix is transitioning from a development-stage biotech to a commercial radiopharmaceutical company. While this hasn't been a smooth ride, its growing portfolio of imaging and therapeutic products gives it multiple shots at long-term value creation.
TechnologyOne Ltd (ASX: TNE)
TechnologyOne is a classic ASX share compounder. Its move to a software-as-a-service model has driven recurring revenue growth, high margins, and strong customer retention across government and enterprise clients. Management believes it can double in size every five years.
WiseTech Global Ltd (ASX: WTC)
WiseTech dominates global logistics software. Its CargoWise platform remains deeply embedded in customers' operations, supporting a long growth runway as global trade digitises. Its shares were hammered in 2025, potentially setting the stage for a big rebound in 2026.
Xero Ltd (ASX: XRO)
Finally, Xero continues to build a powerful ecosystem for small businesses worldwide. With 4.6 million subscribers and expanding services beyond accounting, it still has significant scope to deepen relationships and lift lifetime value. Especially with a total addressable market estimated to be 100 million small to medium sized businesses.
